Clinical Trial Update: A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene [Phase 2]

View source ↗

Summary

Phase 2 study of AB-106 in advanced non-small cell lung cancer with ROS1 fusions is listed as active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AB-106

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING